Published: 23 June 2021
Author(s): Nihal Martis, Matthieu Jamme, Corinne Bagnis-Isnard, Claire Pouteil-Noble, Claire Presne, Cécile Vigneau, Steven Grangé, Stéphane Burtey, Jean-Philippe Coindre, Alain Wynckel, Mohamed A Hamidou, Tarik Kanouni, Elie Azoulay, Miguel Hié, Dominique Chauveau, Agnès Veyradier, Eric Rondeau, Paul Coppo, for the French Reference Centre for Thrombotic Microangiopathies
Issue: October 2021
Section: Original article

The term thrombotic microangiopathy (TMA) defines a syndrome characterised by the association of a peripheral thrombocytopenia, a mechanical haemolytic anaemia and organ failure [1]. Thrombotic thrombocytopenic purpura (TTP) and the haemolytic uremic syndrome (HUS) (including Shigatoxin-associated HUS and atypical HUS [aHUS]) are the two most common forms of TMA. The latter can also occur in association with treatments such as antineoplastic agents, recreational drugs, or various other conditions such as transplantation, malignant hypertension or systemic auto-immune diseases (SAID).

Newsletters

Stay informed on our latest news!